Adaptive, Flatiron Health integrates clonoSEQ MRD testing into OncoEMR

Adaptive Biotechnologies (ADPT) and Flatiron Health announced the integration of Adaptive’s clonoSEQ test for measurable residual disease, MRD, assessment in lymphoid malignancies into OncoEMR, Flatiron’s cloud-based Electronic Medical Record, EMR, platform. “This collaboration with Flatiron demonstrates our shared commitment to empowering providers in community oncology practices, where the majority of Americans receive their cancer care,” said Susan Bobulsky, Chief Commercial Officer, MRD at Adaptive Biotechnologies. “By streamlining access to vital MRD data, we enable community clinicians managing blood cancer patients to make more informed and personalized treatment decisions. We aim to elevate the patient experience by ensuring every care team can readily access and apply the powerful insights that clonoSEQ MRD assessment provides.”